Center Laboratories, Inc. (4123.TWO)
TWD 41.9
(-1.53%)
TWD 41.9
(-1.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.78 Billion TWD | 14.33% |
| 2022 | 5.93 Billion TWD | -36.51% |
| 2021 | 9.34 Billion TWD | 29.26% |
| 2020 | 7.23 Billion TWD | -2.35% |
| 2019 | 7.4 Billion TWD | 50.87% |
| 2018 | 4.9 Billion TWD | -77.09% |
| 2017 | 21.43 Billion TWD | 47.47% |
| 2016 | 14.53 Billion TWD | 11.54% |
| 2015 | 13.02 Billion TWD | 386.21% |
| 2014 | 2.67 Billion TWD | 492.94% |
| 2013 | 451.93 Million TWD | -25.6% |
| 2012 | 607.42 Million TWD | 52.61% |
| 2011 | 398.01 Million TWD | 48.1% |
| 2010 | 268.74 Million TWD | -11.06% |
| 2009 | 302.16 Million TWD | -31.8% |
| 2008 | 443.08 Million TWD | 149.39% |
| 2007 | 177.66 Million TWD | -20.15% |
| 2006 | 222.5 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.38 Billion TWD | 8.82% |
| 2024 Q2 | 8.28 Billion TWD | 12.21% |
| 2023 Q1 | 7 Billion TWD | 17.95% |
| 2023 Q3 | 7.95 Billion TWD | 1.46% |
| 2023 Q4 | 6.78 Billion TWD | -14.72% |
| 2023 FY | 6.78 Billion TWD | 14.33% |
| 2023 Q2 | 7.84 Billion TWD | 12.03% |
| 2022 Q2 | 6.26 Billion TWD | -11.01% |
| 2022 Q4 | 5.93 Billion TWD | -13.2% |
| 2022 FY | 5.93 Billion TWD | -36.51% |
| 2022 Q1 | 7.04 Billion TWD | -24.64% |
| 2022 Q3 | 6.83 Billion TWD | 9.06% |
| 2021 Q4 | 9.34 Billion TWD | -0.76% |
| 2021 FY | 9.34 Billion TWD | 29.26% |
| 2021 Q1 | 8.06 Billion TWD | 11.49% |
| 2021 Q2 | 8.93 Billion TWD | 10.76% |
| 2021 Q3 | 9.42 Billion TWD | 5.47% |
| 2020 Q3 | 6 Billion TWD | 1.09% |
| 2020 Q4 | 7.23 Billion TWD | 20.44% |
| 2020 Q2 | 5.94 Billion TWD | -1.99% |
| 2020 Q1 | 6.06 Billion TWD | -18.17% |
| 2020 FY | 7.23 Billion TWD | -2.35% |
| 2019 FY | 7.4 Billion TWD | 50.87% |
| 2019 Q3 | 7.82 Billion TWD | -15.36% |
| 2019 Q2 | 9.24 Billion TWD | 57.17% |
| 2019 Q1 | 5.88 Billion TWD | 19.78% |
| 2019 Q4 | 7.4 Billion TWD | -5.32% |
| 2018 Q2 | 25.3 Billion TWD | 7.06% |
| 2018 Q1 | 23.63 Billion TWD | 10.28% |
| 2018 FY | 4.9 Billion TWD | -77.09% |
| 2018 Q4 | 4.9 Billion TWD | -78.97% |
| 2018 Q3 | 23.34 Billion TWD | -7.72% |
| 2017 Q3 | 19.66 Billion TWD | 8.76% |
| 2017 Q2 | 18.08 Billion TWD | 19.39% |
| 2017 Q1 | 15.14 Billion TWD | 4.24% |
| 2017 FY | 21.43 Billion TWD | 47.47% |
| 2017 Q4 | 21.43 Billion TWD | 8.96% |
| 2016 Q3 | 14.23 Billion TWD | 1.38% |
| 2016 FY | 14.53 Billion TWD | 11.54% |
| 2016 Q1 | 14.07 Billion TWD | 8.03% |
| 2016 Q2 | 14.03 Billion TWD | -0.26% |
| 2016 Q4 | 14.53 Billion TWD | 2.11% |
| 2015 Q4 | 13.02 Billion TWD | -9.31% |
| 2015 FY | 13.02 Billion TWD | 386.21% |
| 2015 Q3 | 14.36 Billion TWD | 137.66% |
| 2015 Q2 | 6.04 Billion TWD | 78.09% |
| 2015 Q1 | 3.39 Billion TWD | 26.68% |
| 2014 Q1 | 464.91 Million TWD | 2.87% |
| 2014 FY | 2.67 Billion TWD | 492.94% |
| 2014 Q4 | 2.67 Billion TWD | 106.43% |
| 2014 Q3 | 1.29 Billion TWD | 164.83% |
| 2014 Q2 | 490.16 Million TWD | 5.43% |
| 2013 Q2 | 611.65 Million TWD | -3.86% |
| 2013 Q3 | 433.4 Million TWD | -29.14% |
| 2013 FY | 451.93 Million TWD | -25.6% |
| 2013 Q4 | 451.93 Million TWD | 4.28% |
| 2013 Q1 | 636.22 Million TWD | 4.74% |
| 2012 Q2 | 420.31 Million TWD | -2.77% |
| 2012 Q4 | 607.42 Million TWD | 42.83% |
| 2012 Q3 | 425.27 Million TWD | 1.18% |
| 2012 Q1 | 432.28 Million TWD | 8.61% |
| 2012 FY | 607.42 Million TWD | 52.61% |
| 2011 Q3 | 271.81 Million TWD | -0.58% |
| 2011 Q1 | 293.06 Million TWD | 9.05% |
| 2011 Q2 | 273.41 Million TWD | -6.7% |
| 2011 Q4 | 398.01 Million TWD | 46.43% |
| 2011 FY | 398.01 Million TWD | 48.1% |
| 2010 FY | 268.74 Million TWD | -11.06% |
| 2010 Q4 | 268.74 Million TWD | 0.0% |
| 2009 FY | 302.16 Million TWD | -31.8% |
| 2008 FY | 443.08 Million TWD | 149.39% |
| 2007 FY | 177.66 Million TWD | -20.15% |
| 2006 FY | 222.5 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Allied Biotech Corporation | 910.11 Million TWD | -645.614% |
| GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -2301.784% |
| Easywell Biomedicals, Inc. | 589.98 Million TWD | -1050.185% |
| TTY Biopharm Company Limited | 3.36 Billion TWD | -101.437% |
| Synmosa Biopharma Corporation | 3.62 Billion TWD | -87.06% |
| Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | -2.055% |
| Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -4113.517% |
| Orient Pharma Co., Ltd. | 892.18 Million TWD | -660.602% |
| InnoPharmax Inc. | 48.64 Million TWD | -13848.803% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -2014.05% |
| Excelsior Biopharma Inc. | 472.87 Million TWD | -1335.045% |
| DV Biomed Co., Ltd. | 765.87 Million TWD | -786.04% |
| Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | -999.952% |
| Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -2315.953% |
| UniPharma Co., Ltd. | 37.4 Million TWD | -18043.774% |
| Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | -568.35% |
| Alar Pharmaceuticals Inc. | 76.08 Million TWD | -8818.442% |
| Winston Medical Supply Co., Ltd. | 373.87 Million TWD | -1715.033% |
| Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -13548.062% |
| Bioray Biotech Co., Ltd | 108.75 Million TWD | -6139.842% |
| TSH Biopharm Corporation Limited | 133.62 Million TWD | -4978.318% |